Haier Biomedical updates on share buyback progress

Qingdao Haier Biomedical Co., Ltd. has provided an update on its share repurchase program through centralized competitive bidding. As of October 31, 2025, the company has cumulatively repurchased 2,590,257 shares, representing 0.8147% of its total share capital of 317,952,508 shares. The total amount spent on these repurchases stands at 84,115,620.15 yuan, excluding transaction fees. The repurchased shares were acquired at prices ranging from 29.86 yuan to 34.69 yuan per share.

The company's board of directors initially approved the share repurchase plan on January 13, 2025, with a target repurchase amount between 100 million yuan and 200 million yuan. The repurchase period extends from January 14, 2025, to January 13, 2026. The repurchased shares are primarily intended for employee stock ownership plans or equity incentives.

Following an annual equity distribution in 2024, the maximum repurchase price was adjusted to no more than 49.5367 yuan per share, effective June 6, 2025. Haier Biomedical affirmed its commitment to adhering to all relevant regulations and will continue to make repurchase decisions and disclose progress in a timely manner.